二氯化镭[223Ra](Radium Ra-223 Dichloride) - 药物靶点：DNA_在研适应症：前列腺癌，骨转移癌，去势抵抗性前列腺癌_专利_临床

概要

基本信息

药物类型

小分子化药、治疗用放射药物

别名

Alpharadin、Radium chloride Ra-223、Radium Ra 223 dichloride

+ [20]

靶点

DNA

作用方式

抑制剂

作用机制

DNA抑制剂(DNA抑制剂)、电离辐射发射源

治疗领域

肿瘤泌尿生殖系统疾病皮肤和肌肉骨骼疾病

在研适应症

前列腺癌骨转移癌去势抵抗性前列腺癌+ [7]

非在研适应症

晚期前列腺癌骨病HR阴性/HER2阳性乳腺癌+ [8]

原研机构

Bayer AG

在研机构

Bayer AG

拜耳医药保健有限公司

Institute For Energy Technology

+ [6]

非在研机构

Bayer Plc

权益机构

Bayer Pharma AG

中国同辐股份有限公司

最高研发阶段批准上市

首次获批日期

美国 (2013-05-15),

去势抵抗性前列腺癌

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、特殊审批 (中国)、孤儿药 (韩国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式Cl2Ra

InChIKeyRWRDJVNMSZYMDV-SIUYXFDKSA-L

CAS号444811-40-9

关联

117

项与二氯化镭[223Ra] 相关的临床试验

NCT07717099

/ Not yet recruiting临床2期IIT

Quantitative Unified Assessment of Novel Triplet Therapy and Unconventional Maintenance With Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial

GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination lies in the potential additive or synergistic benefits that may arise from concurrently targeting androgen receptor signaling pathways and bone metastases.

开始日期2026-09-01

申办/合作机构

Mfar Constructions Pvt Ltd.

[+1]

CTIS2025-524208-31-00

/ Not yet recruiting临床2期

Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.

开始日期2026-04-02

申办/合作机构

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

NL-OMON57275

/ RecruitingN/A

PSMA-PET/CT and genomic alterations for future selection of patients with metastatic castration resistant prostate cancer (mCRPC) for Radium-223 treatment. - The Radium-select study

开始日期2025-03-12

申办/合作机构-

100 项与二氯化镭[223Ra] 相关的临床结果

登录后查看更多信息

100 项与二氯化镭[223Ra] 相关的转化医学

登录后查看更多信息

100 项与二氯化镭[223Ra] 相关的专利（医药）

登录后查看更多信息

944

项与二氯化镭[223Ra] 相关的文献（医药）

2026-07-01·CANCER

Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib

Article

作者: Hussain, Arif ; Kyriakopoulos, Christos E. ; Shapiro, Geoffrey I. ; Ajmera, Archana ; Olson, Adam ; Xie, Wanling ; Saraiya, Biren ; Parikh, Mamta ; McKay, Rana R. ; Araneta, Arlene ; Parikh, Rahul ; Folefac, Edmund

Abstract:

Background:

The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.

Methods:

Patients were randomized 1:1 to olaparib plus radium‐223 (arm A) or radium‐223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy–Prostate (FACT‐P) and Brief Pain Inventory (BPI) at baseline and every 12 weeks. Clinically meaningful changes were defined as a ≥10‐point change in FACT‐P total score and a ≥30% or ≥2‐point change in BPI score. Mixed‐effects analysis‐of‐covariance models assessed PRO changes with adjustment for baseline characteristics among patients with baseline and ≥1 postbaseline assessment within 24 weeks.

Results:

Of 114 treated patients, 74 (65%) were evaluable (arm A, n = 40; arm B, n = 34). Baseline characteristics were balanced, with a median age of 70–72 years and Eastern Cooperative Oncology Group performance status of 1 in 60%–62%, prior docetaxel in 50%–55%, >20 BM in 45%–47%, and pain medication use in 60%–72% of patients. No significant differences in FACT‐P total score change was observed at Week 12 (−4.87; 95% CI, −13.4 to 3.62) or Week 24 (1.79; 95% CI, −8.28 to 11.9). BPI pain severity did not differ at Week 12 (0.44; 95% CI, −0.44 to 1.33) or Week 24 (−0.20; 95% CI, −1.32 to 0.93). Arm B showed greater improvement in BPI pain interference at Week 12 (1.09; 95% CI, 0.14 to 2.05), which was not sustained at Week 24.

Conclusions:

The addition of olaparib to radium‐223 was not associated with significant detriment to PROs or pain, which supports the tolerability of this combination.

2026-07-01·Clinical and Translational Radiation Oncology

Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models

Article

作者: Toner, Aislinn ; Wilson, Melissa LaBonte ; Wright, Timothy C ; Savage, Kienan I ; Dunne, Victoria L ; Prise, Kevin M ; O'Sullivan, Joe M

INTRODUCTION:

Personalised medicine approaches are redefining the therapeutic landscape for men with metastatic castration-resistant prostate cancer (mCRPC). While poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated clinical benefit in patients with BRCA1/2 mutant tumours, the therapeutic efficacy of these inhibitors in Ataxia-telangiectasia mutated (ATM)-mutated prostate cancer patients remains modest, highlighting the need for alternative treatment strategies. This study aimed to elucidate the impact of ATM loss on radiobiological and immune responses to different radiation modalities in prostate cancer models.

METHODS:

Isogenic CRISPR Cas-mediated ATM-deficient and wild-type (WT) cells were treated with X-rays or Radium-223 dichloride (²²³Ra). Cellular radiosensitivity was measured using clonogenic assays and 53BP1 immunofluorescence assessed DNA damage. Cell cycle distribution and apoptosis were analysed by flow cytometry. Innate immune activation was assessed using cGAS immunofluorescence and quantitative PCR of CCL5, CXCL10 and IFIT2.

RESULTS:

²²³Ra significantly increased radiosensitivity in comparison to X-rays which was amplified by ATM loss. ²²³Ra exposure in ATM deficient cells induced significantly greater levels of DNA damage as measured by persistent 53BP1 foci at 24h, distinct G2 accumulation and elevated levels of apoptosis in PC-3 and DU145 ATM-deficient cells in comparison to either X-rays or WT counterparts (p < 0.05). Furthermore, ²²³Ra triggered cGAS positive micronuclei and upregulation of STING driven inflammatory genes, particularly in ATM-deficient cells (p < 0.05).

CONCLUSIONS:

These findings demonstrate that ATM-deficiency enhances radiobiological response and amplifies immune activation to ²²³Ra, supporting further pre-clinical evaluation of ATM loss as a determinant of response and therapeutic target to optimise ²²³Ra based strategies for mCRPC.

2026-06-20·JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

Article

作者: Madison, Russell ; Manning, Danielle K. ; Parikh, Rahul ; Kochupurakkal, Bose ; Pasquina, Lincoln W. ; Olson, Adam ; Van Allen, Eliezer ; Shapiro, Geoffrey I. ; Gasco, Amaya ; Ajmera, Archana ; Xie, Wanling ; Saraiya, Biren ; Ivy, Percy ; Childress, Merrida ; Araneta, Arlene ; Parikh, Mamta ; McKay, Rana R. ; Folefac, Edmund ; Jamieson, Christina ; Hussain, Arif ; Kyriakopoulos, Christos E. ; Clifford, Sarah

PURPOSE:

Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibition and radiation. After phase I dose-finding, we conducted a randomized phase II trial to assess efficacy and safety of this combination versus radium-223.

PATIENTS AND METHODS:

Men with mCRPC and ≥2 bone metastases (BM) were randomly assigned 1:1 to olaparib (200 mg twice daily) plus radium-223 (55 kBq/kg intravenous once every 4 weeks × 6 doses) or radium-223. Crossover was allowed at progression. The primary end point was investigator-assessed radiographic progression-free survival (rPFS).

RESULTS:

A total of 120 patients were randomly assigned. Most had prior androgen receptor pathway inhibitor exposure (96%), 52% had received docetaxel, 47% had >20 BM, and 90% received bone-protecting agents. The combination significantly improved rPFS (median 8.9 v 4.7 months; hazard ratio [HR], 0.50 [one-sided 90% CI, 0.35 to 0.70]; one-sided P = .0042). The benefit was most pronounced in patients without prior docetaxel (13.7 v 5.7 months; HR, 0.24 [90% CI, 0.15 to 0.40]) and those with ≤20 BM (13.4 v 4.2 months; HR, 0.21 [90% CI, 0.13 to 0.33]). The 1-year cumulative incidence of symptomatic skeletal-related events was lower with the combination (12.7% v 22.9%). Median overall survival was similar (20.2 v 21.1 months). Grade ≥3 treatment-related adverse events occurred in 56% versus 33% (combination v radium-223), primarily hematologic, including lymphopenia (31% v 9.1%), anemia (22% v 16%), and thrombocytopenia (6.8% v 3.6%).

CONCLUSION:

Olaparib plus radium-223 significantly prolonged rPFS compared with radium-223 in men with mCRPC and BM. Despite increased hematologic toxicity, the regimen was manageable and supports further exploration of DNA damage–targeted strategies in this population.

235

项与二氯化镭[223Ra] 相关的新闻（医药）

2026-07-28

·生物谷

J Nuclear Med：一管血里的战争！液体活检为前列腺癌治疗“精准导航”

研究人员发现，通过检测血液中的循环肿瘤DNA（ctDNA），不仅能在治疗启动前预判患者预后，还能在治疗过程中动态监测疗效变化。前列腺癌是男性泌尿系统最常见的恶性肿瘤之一，WHO数据显示，全球每年新发病例超过140万例，其中约10%至20%的患者在确诊时已处于高风险或转移性阶段。对于转移性去势抵抗性前列腺癌（mCRPC）患者而言，治疗选择尤为有限，而骨转移更是这一群体中最常见的死亡相关并发症。氯化镭-223（223Ra）作为一种骨靶向放射配体疗法，已被证实能延长骨转移性mCRPC患者的总生存期并改善生活质量。然而一个尴尬的现实始终存在：同样接受该治疗的患者，临床结局可能天差地别，而临床上长期缺乏有效工具来预判谁才是真正的获益者。日前，发表在国际杂志Journal of Nuclear Medicine上题为“Circulating Tumor DNA Genomic Profiling in 223Ra -Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study”的研究报告中，来自日本多中心的研究人员通过进行一项前瞻性观察性研究，为这一困境提供了破局思路。文章中，研究人员发现，通过检测血液中的循环肿瘤DNA（ctDNA），不仅能在治疗启动前预判患者预后，还能在治疗过程中动态监测疗效变化，这意味着，未来的临床医生或许只需抽一管血，就能更早看清这场战役的走向。文章中，研究人员入组了93例骨转移性mCRPC患者，在223Ra治疗开始前及治疗结束时分别采集外周血，分离血浆中的游离DNA并搭配配对白细胞DNA作为对照，利用一个包含88个关键癌症相关基因的检测面板进行靶向测序。最终，84例基线样本和74例治疗结束样本成功完成测序，其中68例具有完整的前后配对数据。在此基础上，研究人员将ctDNA谱图与患者的生化指标应答、影像学无进展生存期（rPFS）以及总生存期（OS）进行了系统的关联分析。结果相当清晰，基线时ctDNA占比达到或超过5%的患者，其rPFS和OS均显著缩短。更值得关注的是，TP53基因变异、PTEN基因缺失或突变，以及细胞周期通路相关基因的异常，同样与较差的无进展生存和总生存密切相关。换句话说，治疗前血液中肿瘤DNA含量较高，或者携带上述特定基因变异的患者，对223Ra的应答往往不尽如人意。这为临床筛选更适合该疗法的“优势人群”提供了直接的分子依据。研究人员对比了治疗前后ctDNA占比及PTEN基因变异状态的变化后发现，这些指标的动态波动与患者的疾病轨迹高度吻合。治疗期间ctDNA水平明显下降的患者，往往提示较好的治疗应答；反之，若ctDNA持续升高或PTEN变异状态发生不利转变，则多预示着疾病进展或耐药出现。这种“实时液体活检”策略，正好弥补了传统影像学评估滞后、无法频繁进行的短板。综合来看，这项研究首次在223Ra治疗背景下，系统验证了ctDNA检测的双重价值：治疗前的基线检测可作为预后分层工具，帮助识别高危患者；治疗过程中的连续检测则能反映药物生物学效应，辅助早期识别耐药苗头；这项发现并非要取代临床判断，而是为医生提供一块更清晰的“导航仪表盘”，让治疗决策有据可依，让患者管理更加个体化。当然，这项技术距离大规模临床普及仍需更多验证。但一个显而易见的事实是：当癌症治疗进入精准医学时代，影像学和传统血清标志物已不足以支撑全部决策，而ctDNA检测凭借其无创、可重复、信息量大等优势，正在成为连接实验室与病床之间的一条新桥梁。（生物谷Bioon.com）参考文献： Masaki Shiota,Maki Fujiwara,Takayuki Sumiyoshi, et al. Circulating Tumor DNA Genomic Profiling in 223 Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study. Journal of Nuclear Medicine(2026). DOI: 10.2967/jnumed.126.272073.

2026-07-28

·BioSpace

Starget Pharma Expands Scientific Advisory Board with Appointment of Two Global Leaders in Radiopharmaceutical Therapy

Dr. Oliver Sartor brings more than 35 years advancing the clinical development and commercialization of oncology and radiopharmaceuticals Professor Michael Hofman brings more than 20 years pioneering molecular imaging and precision radiotheranostics SHREVEPORT, La., July 28, 2026 (GLOBE NEWSWIRE) -- Starget Pharma Inc. (Starget), a U.S. clinical-stage radiopharmaceutical company, today announced the appointment of Oliver Sartor, MD, and Professor Michael Hofman, MBBS, FRACP, FAANMS to its Scientific Advisory Board (SAB), further strengthening the Company's scientific leadership as it advances multiple radioligand programs toward the clinic from its AI-powered discovery platform. Dr. Sartor and Professor Hofman are internationally recognized leaders in oncology and radiopharmaceutical medicine. Their decades of experience spanning scientific innovation through clinical development have helped establish radioligand therapy as an emerging pillar of cancer treatment. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “We are honored to welcome Oliver and Michael to our Scientific Advisory Board,” said Sigal Kalmanson Cusnir, CEO and Co-Founder of Starget Pharma. “Their deep experience advancing radioligand therapies into clinical practice will help shape our development strategy as we further advance our next-generation radioligand pipeline.” Dr. Sartor added, “Starget’s platform combines artificial intelligence with advanced peptide engineering to design radioligands with the potential to improve tumor targeting and pharmacologic performance. I look forward to working with the team to help expand the reach of radioligand therapy across a broader range of cancer targets.” Professor Hofman added, “Radiotheranostics offers a unique advantage in drug development by showing where a radioligand goes before treatment. Starget’s approach using insights from imaging to inform AI-driven optimization has the potential to accelerate the development of more effective radiopharmaceuticals, and I look forward to helping advance that vision.” Oliver Sartor, MD is an internationally recognized medical oncologist and one of the world’s leading experts in prostate cancer and radiopharmaceutical therapies. He serves as Director of the Transformational Prostate Cancer Research Center at East Jefferson General Hospital Cancer Center and previously served as Director of Radiopharmaceutical Clinical Trials at Mayo Clinic. He has led numerous landmark clinical trials that resulted in the approval of transformative therapies, including Xofigo ® (radium-223), Pluvicto ® (¹⁷⁷Lu-PSMA-617), Jevtana ® (cabazitaxel), and Quadramet ® (samarium-153). Dr. Sartor has authored more than 600 peer-reviewed publications. Professor Michael Hofman, MBBS, FRACP, FAANMS, is a globally recognized nuclear medicine physician and physician-scientist and a pioneer in molecular imaging and theranostics. Serving as an independent advisor, he is based at Peter MacCallum Cancer Centre and the University of Melbourne, where he led landmark clinical trials, including proPSMA, TheraP, UpFrontPSMA and PRIMARY2, that have helped establish PSMA imaging and radioligand therapy as standards of care for prostate cancer. His research spans radiopharmaceutical discovery, clinical translation and imaging biomarkers, with publications in leading medical journals including The Lancet . About Starget Pharma Inc. Starget Pharma is a clinical-stage radiopharmaceutical company developing next-generation peptide radioligand therapies for cancer, with operations in the U.S. and Israel. The Company’s AI-powered platform integrates computational peptide design, theranostic imaging, and biological feedback to accelerate the discovery and optimization of radioligands with the potential to improve tumor targeting and pharmacologic performance. Starget Pharma is advancing a wholly owned pipeline of differentiated radioligand therapies across a broad range of cancers, including lead programs targeting SSTR3 and GRPR that are designed to address significant unmet needs with first-in-class and best-in-class potential. Learn more at . Investor Contact Chuck Padala LifeSci Advisors, LLC chuck@lifesciadvisors.com

高管变更

2026-07-27

·汇佳生物

Kairos Pharma 宣布与 Bayer 达成战略合作，联合用药提升 XOFIGO 针对转移性前列腺癌的治疗效果

该联合疗法可覆盖全球规模 5.7 亿至 13 亿美元的目标市场；ENV-105Ⅱ 期临床数据显示，针对耐药型转移性去势抵抗性前列腺癌（mCRPC），临床获益率达 86% 临床阶段生物制药企业 Kairos Pharma, Ltd.（NYSE American: KAPA）专注攻克肿瘤耐药难题，近日宣布与 Bayer 达成战略合作，将开展临床试验评估 Kairos Pharma 核心抗体药物 ENV-105（carotuximab）联合 Bayer 的 XOFIGO（Ra-223 二氯化镭）用于合并骨转移的转移性去势抵抗性前列腺癌（mCRPC）的治疗效果。 Kairos Pharma 目前围绕 ENV-105 布局两项临床试验：一项针对 EGFR 突变非小细胞肺癌的 Ⅰ 期临床试验，以及一项针对去势抵抗性前列腺癌的 Ⅱ 期临床试验。去年，Kairos Pharma 公布该 Ⅱ 期临床试验积极中期疗效数据：患者中位无进展生存期超 13 个月，相较标准治疗方案实现显著提升，相关数据已于 2025 年在柏林举办的欧洲肿瘤内科学会（ESMO）年会上公布。 XOFIGO 是首款、也是目前唯一一款获美国食品药品监督管理局（FDA）批准的 α 射线放射性药物，适用于伴随症状性骨转移的转移性去势抵抗性前列腺癌。目前 Bayer 正在推进多项 XOFIGO 联合用药研究，其中 Ⅲ 期 PEACE-3 临床试验结果显示，XOFIGO 联合恩杂鲁胺可使患者死亡风险降低 24%（风险比 HR=0.76，P=0.009）。 Kairos Pharma 首席执行官、医学博士 John Yu 表示：“肿瘤耐药始终是晚期前列腺癌治疗中最大的难题之一，和众多标准治疗药物一样，XOFIGO 的疗效也会随治疗推进逐步下降。ENV-105 已被证实可让耐药肿瘤重新对现有治疗药物产生应答，且药物安全性表现优异。本次与 Bayer 的合作，是我们研发使命中的重要里程碑，我们致力于为转移性前列腺癌患者带来疗效更持久、效果更突出的联合治疗方案。” 此前已发表的临床前研究证实，ENV-105 在前列腺癌动物模型中具备放疗增敏作用。患者接受标准雄激素受体抑制剂治疗或电离辐射后，体内 CD105 蛋白表达水平会显著上调，该蛋白会激活促进肿瘤存活的 BMP-SMAD 信号通路，最终诱发肿瘤治疗耐药。使用 ENV-105 靶向抑制 CD105，能够重新激活耐药肿瘤对治疗的敏感性，有望延长、加深 XOFIGO 靶向 α 放射治疗带来的肿瘤缓解效果。公司首席科学官、首席研究员 Neil Bhowmick 博士表示：“目前已有多类药物的相关研究证实，CD105 是介导肿瘤耐药的核心通路靶点。结合 XOFIGO 近期 Ⅲ 期临床试验取得的突破性进展，本次合作兼具充分的科学依据与重要的临床价值。” 关于 Kairos Pharma Ltd. Kairos Pharma Ltd. 总部位于美国加利福尼亚州洛杉矶，在肿瘤治疗药物研发领域处于前沿地位。公司依托结构生物学技术，攻克肿瘤治疗过程中的药物耐药与免疫抑制难题。Kairos Pharma 核心候选药物 ENV-105 是一款靶向 CD105 的抗体。CD105 蛋白被证实是肿瘤患者接受标准治疗后，产生耐药、疾病复发的关键驱动因子。ENV-105 通过靶向 CD105 逆转肿瘤耐药，让多种肿瘤的标准治疗方案重新恢复治疗活性。点击下方阅读原文，了解详情往期回顾 Bayer 公布心脏淀粉样变性放射性示踪剂研究积极结果 Bayer 收购 Attralus 创新泛淀粉样蛋白放射性示踪剂，拓展分子影像业务版图 AACR特辑4：Bayer启动靶向GPC3的I期研究，使用Ac-225放射性药物治疗晚期肝细胞癌患者汇佳生物专注于转化医学领域的前沿研究及临床转化应用技术，业务涵盖生物标志物和药物靶标技术，新型诊断试剂及治疗药物的研发，相关仪器设备的开发及临床转化技术的应用，实现了产、医、研的融合发展。媒体合作/科研宣传/产品咨询长按二维码，联系我们

100 项与二氯化镭[223Ra] 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	二氯化镭[223Ra]	V10XX03	DB08913

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
前列腺癌	中国	Institute For Energy Technology	2020-08-26
骨转移癌	欧盟	Bayer AG	2013-11-13
骨转移癌	冰岛	Bayer AG	2013-11-13
骨转移癌	列支敦士登	Bayer AG	2013-11-13
骨转移癌	挪威	Bayer AG	2013-11-13
去势抵抗性前列腺癌	美国	Bayer HealthCare Pharmaceuticals, Inc.	2013-05-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
去势敏感前列腺癌	临床3期	-	Bayer AG	2023-09-01
转移性前列腺癌	临床3期	-	Bayer AG	2023-09-01
转移性去势抵抗性前列腺癌	临床3期	中国	Bayer AG	2013-03-26
转移性去势抵抗性前列腺癌	临床3期	新加坡	Bayer AG	2013-03-26
转移性去势抵抗性前列腺癌	临床3期	韩国	Bayer AG	2013-03-26
转移性去势抵抗性前列腺癌	临床3期	中国台湾	Bayer AG	2013-03-26
激素依赖性前列腺癌	临床2期	西班牙	Bayer AG	2026-09-01
转移性前列腺腺癌	临床2期	美国	Bayer AG	2022-04-28
转移性前列腺腺癌	临床2期	巴西	Bayer AG	2022-04-28
寡转移性前列腺癌	临床2期	美国	Bayer AG	2018-02-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04090398 (ETCTN 10302, ASCO2026)	临床2期	转移性乳腺癌 HER2-negative	70	Radium-223 dichloride + Paclitaxel	鏇憲構襯觸窪簾範窪艱(簾艱獵夢醖衊網簾廠糧) = 蓋衊積鹹願餘壓獵製選鹹夢繭簾廠願窪遞遞夢 (壓廠積構築廠餘壓遞觸 ) 更多	不佳	2026-05-29
				Paclitaxel	鏇憲構襯觸窪簾範窪艱(簾艱獵夢醖衊網簾廠糧) = 齋製顧願醖遞淵構願醖鹹夢繭簾廠願窪遞遞夢 (壓廠積構築廠餘壓遞觸 ) 更多
NCT04109729 (ASCO2026)	临床1期	转移性去势抵抗性前列腺癌	39	radium-223+nivolumab	鹹糧範構繭醖遞鏇鑰觸(襯願淵簾鏇鹹鏇構廠餘) = 鑰選鏇鏇齋選鏇醖獵製製艱顧壓範鬱衊鏇餘觸 (繭構艱獵窪網艱築餘鏇 ) 更多	积极	2026-05-29
NCT03317392 (COMRADE, CTgov)	临床1/2期	转移性前列腺恶性肿瘤 \| 转移性前列腺腺癌 \| 转移性去势抵抗性前列腺癌	132	Computed Tomography+Radium Ra 223 Dichloride+Olaparib (Phase II Arm I (Radium Ra 223 Dichloride, Olaparib))	膚壓鏇積醖齋網蓋鏇築(鏇選遞築憲憲鏇網糧艱) = 構繭遞鹹蓋廠窪繭鏇積衊餘糧範範襯糧築鹽淵 (膚鹹遞積積選窪蓋鹽繭, 顧襯襯獵憲醖窪遞壓鹽 ~ 鏇築憲淵齋鏇網網觸鹽) 更多	-	2026-05-05
				Computed Tomography (Phase II Arm II (Radium Ra 223 Dichloride))	膚壓鏇積醖齋網蓋鏇築(鏇選遞築憲憲鏇網糧艱) = 構積鬱糧衊淵範範觸願衊餘糧範範襯糧築鹽淵 (膚鹹遞積積選窪蓋鹽繭, 繭鑰選鑰顧餘淵餘衊膚 ~ 齋網齋衊製鹽繭膚鏇淵) 更多
NCT03361735 (CTgov)	临床2期	去势敏感前列腺癌 \| 转移性前列腺癌 \| 前列腺腺癌	25	Radium Ra 223 Dichloride (De Novo mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))	窪鬱選醖鹽築餘蓋顧襯(蓋鹽築鏇顧膚構糧遞鏇) = 繭顧鑰鹽顧獵齋築壓艱繭網遞襯齋餘窪餘觸觸 (遞襯網築選淵選餘艱觸, 廠遞夢鏇糧鏇構願鏇壓 ~ 襯醖鏇醖觸窪鹹鬱獵鏇) 更多	-	2026-04-09
				Radium Ra 223 Dichloride (Oligoprogressive mCSPC Patients. Treatment (Hormone Therapy, SBRT, Radium Ra 223 Dichloride))	窪鬱選醖鹽築餘蓋顧襯(蓋鹽築鏇顧膚構糧遞鏇) = 製鏇衊壓蓋齋鬱餘壓選繭網遞襯齋餘窪餘觸觸 (遞襯網築選淵選餘艱觸, 鹽築襯鹽窪築願艱觸網 ~ 襯夢艱構窪憲壓膚醖願) 更多
NCT02194842 (PEACE-3 \| EORTC1333, ASCO_GU2026 \| BusinessWire) 人工标引	临床3期	转移性去势抵抗性前列腺癌	446	Enzalutamide + Radium-223	鹹繭積襯鬱簾襯簾遞鹽(餘築獵獵憲選壓夢鬱齋) = 構鹹觸鬱積醖鹽鹽獵鹽顧構顧醖鑰獵衊餘鹹顧 (網壓夢選範鏇餘糧鏇膚 ) 更多	积极	2026-02-26
				Enzalutamide	鹹繭積襯鬱簾襯簾遞鹽(餘築獵獵憲選壓夢鬱齋) = 憲鑰襯網築鬱膚艱淵遞顧構顧醖鑰獵衊餘鹹顧 (網壓夢選範鏇餘糧鏇膚 ) 更多
NCT04206319 (ASCO_GU2026 \| ASCO2026)	临床2期	非转移性前列腺癌	24	Radium-223 (PET-positive bone findings + biochemically recurrent prostate cancer)	廠範繭糧顧糧夢襯襯鬱(憲積醖憲壓製糧窪膚鹹) = 衊範窪窪顧壓積襯積醖鹽遞艱鏇顧選願鹽餘網 (製蓋壓糧鑰遞蓋構膚願 ) 更多	积极	2026-02-26
ASCO_GU2026	N/A	转移性去势抵抗性前列腺癌	661	Radium-223	艱齋鑰夢齋糧獵壓簾廠(餘範齋願鬱願壓壓艱製) = 衊淵觸淵夢衊衊糧膚餘壓窪糧觸範選襯觸蓋遞 (繭糧蓋築膚構窪壓憲鹹, 10.2 ~ 12.1)	积极	2026-02-26
				Radium-223 (PTEN, TP53, or RB1 alterations)	艱齋鑰夢齋糧獵壓簾廠(餘範齋願鬱願壓壓艱製) = 築襯獵願糧齋鏇壓壓築壓窪糧觸範選襯觸蓋遞 (繭糧蓋築膚構窪壓憲鹹 )
NCT02141438 (REASSURE, ASCO_GU2026)	N/A	转移性去势抵抗性前列腺癌	1,472	Radium-223	夢膚鑰築獵簾積膚鏇製(鏇餘積積鬱範鹹憲糧憲) = 鏇遞鑰窪構積衊糧鏇願願窪糧範繭積積遞選選 (蓋範窪淵衊繭蓋蓋製選, 41.6 ~ 70.3) 更多	积极	2026-02-26
				Radium-223	夢膚鑰築獵簾積膚鏇製(鏇餘積積鬱範鹹憲糧憲) = 齋襯選膚遞糧糧簾積鹽願窪糧範繭積積遞選選 (蓋範窪淵衊繭蓋蓋製選, 22.1 ~ 32.2) 更多
ASCO_GU2026	N/A	转移性去势抵抗性前列腺癌	386	Radium-223 + Enzalutamide	鹹選鏇醖獵壓膚繭憲網(襯鬱糧簾構醖鑰夢鑰衊): RR = 3.09, P-Value = 0.0015 更多	积极	2026-02-26
				ADT alone
NCT04037358 (RAVENS, CTgov)	临床2期	寡转移性前列腺癌	64	Radium-223+stereotactic ablative radiotherapy (SABR) (Radium-223 and SABR)	積壓築鬱齋蓋選觸淵蓋(壓襯膚鏇簾鏇築艱築糧) = 顧積艱蓋顧遞鏇積鬱醖鹹網蓋窪簾夢糧餘衊窪 (蓋醖積膚壓顧製繭簾壓, 選鹽夢襯簾觸選觸觸構 ~ 鏇廠淵繭構齋憲鏇膚積) 更多	-	2025-12-19
				stereotactic ablative radiotherapy (SABR) (SABR)	積壓築鬱齋蓋選觸淵蓋(壓襯膚鏇簾鏇築艱築糧) = 鹽觸憲艱選衊齋膚鬱夢鹹網蓋窪簾夢糧餘衊窪 (蓋醖積膚壓顧製繭簾壓, 顧範顧壓糧廠網淵衊餘 ~ 顧製鏇築蓋網鹽鹹簾鑰) 更多